Colwell J A, Chambers A, Laimins M
Diabetes. 1975 Jul;24(7):684-7. doi: 10.2337/diab.24.7.684.
Irreversible second-phase aggregation of platelets in diabetic patients is prevented in vitro by 5, 8, 11, 14-eicosatetraynoic acid (TYA), a competitive inhibitor of the labile aggregation-stimulating substance (LASS) which is formed from arachidonic acid. Thus, inhibition of prostaglandin synthesis inhibits platelet aggregation in diabetic subjects. These findings indicate that platelets from diabetics are subject to control by intracellular mechanisms operative in the regulation of platelet function in normal individuals.
在体外，糖尿病患者血小板不可逆的第二阶段聚集可被5,8,11,14-二十碳四炔酸（TYA）阻止，TYA是一种不稳定的聚集刺激物质（LASS）的竞争性抑制剂，LASS由花生四烯酸形成。因此，前列腺素合成的抑制可抑制糖尿病患者的血小板聚集。这些发现表明，糖尿病患者的血小板受正常个体中调节血小板功能的细胞内机制控制。
